drugset / Trial / NCT01122251

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

NCT01122251

Phase 2 Completed 441 enrolled LG Life Sciences
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure. The study will investigate the dose response relationship for the combinations and monotherapies.

Timeline

Start
2009-12
Primary completion
2010-05
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lercanidipine Small molecule 10 mg
Subject Lercanidipine Small molecule 20 mg
Subject Valsartan Small molecule 80 mg
Subject Valsartan Small molecule 160 mg